Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy: A randomized, double-blind trial

Neurosciences

Volumn 19, Issue 3, 2014, Pages 192-198

  Razazian, Nazanin ^a   Baziyar, Maryam ^a   Moradian, Nasrin ^a   Afshari, Daryoush ^a   Bostani, Arash ^a   Mahmoodi, Marziyeh ^b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PREGABALIN; VENLAFAXINE; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; ASTHENIA; BULIMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; EDEMA; FEMALE; HEADACHE; HUMAN; IMPOTENCE; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MOOD; NAUSEA; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP QUALITY; SOMNOLENCE; VISUAL ANALOG SCALE; VOMITING; AFFECT; AGED; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; SLEEP; TREATMENT OUTCOME;

ADULT; AFFECT; AGED; ANALGESICS; ANALGESICS, NON-NARCOTIC; CARBAMAZEPINE; CYCLOHEXANOLS; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SEROTONIN UPTAKE INHIBITORS; SLEEP; TREATMENT OUTCOME;

EID: 84907762449     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci 2001; 189: 3-5.
2. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220-2224.
3. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
4. Backonja MM, Serra J. Pharmacological management part 1: better-studied neuropathic pain diseases. Pain Med 2004; 5 Suppl 1: 28-47. Review.
5. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freedman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
6. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-1795.
7. Jia HY, Li QF, Song PD, AN ZM, Liu YP, Ran XW, et al. Effect of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial. Chin J Evid Based Med 2006; 6: 321-327.
8. Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012; 44: 51-56.
9. Leibson CL, Williamson DF, Melton LJ 3rd, Palumbo PJ, Smith SA, Ransom JE, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care 2001; 24: 1584-1589.
10. Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs 2011; 71: 557-589.
11. Kamei J, Mizoguchi H, Narita M, Tseng LF. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs 2001; 10: 1653-1664.
12. Habib AA, Brannagan TH 3rd. Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep 2010; 10: 92-100.
13. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007; 67: 569-585.
14. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486.
15. Reips UD, Funke F. Interval-level measurement with visual analogue scales in internet based research: VAS Generator. Behavior Res Methods 2008; 40: 699-704.
16. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-121.
17. Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med 2008; 33: 389-394.
18. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76: 1786-1765.
19. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697-706.
20. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscular Dis 2001; 3: 53-62.
21. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician 2010; 82: 151-158.
22. Chakrabarti AK, Samantary SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Aust N Z J Med 1976; 6: 565-568.
23. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-2110.
24. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-260.
25. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-638.
26. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkennohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trials of flexible and fixed-dose regimens. Pain 2005; 115: 254-263.
27. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7: 51-54.
28. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41: 968-975.
29. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 2006; 46: 1151-1160.
30. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012; 122: 60-68.
31. Bostani A, Rajabi A, Moradian N, Razazian N, Rezaei M. The effects of cinnarizine versus sodium valproate in migraine prophylaxis. Int J Neurosci 2013; 123: 487-493.